"INCY was more interested in EU operation rather than ponatinib, otherwise they would have agreed to pay much higher portion of OPTIC-2L trial expense because it is a completely outside of US trial."
Bingo! The $15 million toward the trial from INCY was nothing but a token. Actually, it would have come across as a better for Ariad if they didn't contribute anything. $15 million is so nothing..
Market Data 
Markets 
AI
